Quantitative analysis of multidrug resistance gene expression in human osteosarcomas
1996

MDR1 Expression in Osteosarcomas

Sample size: 77 publication Evidence: moderate

Author Information

Author(s): PD Lee, SE Noble-Topham, RS Bell, IL Andrulis

Primary Institution: University of Toronto

Hypothesis

Does MDR1 mRNA expression in osteosarcomas vary with location within the tumour, following chemotherapy, or after metastasis?

Conclusion

MDR1 expression levels in osteosarcomas do not vary greatly with location, chemotherapy, or metastasis, suggesting some tumours may be intrinsically resistant to doxorubicin.

Supporting Evidence

  • Specimens from multiple locations in six tumours showed little variation in MDR1 expression.
  • In 16 of 20 cases, MDR1 levels did not change appreciably after chemotherapy.
  • Eight of ten specimens before and after metastasis showed constant MDR1 mRNA levels.

Takeaway

This study looked at how a gene related to drug resistance behaves in bone cancer. It found that the levels of this gene don't change much even after treatment.

Methodology

The study used a modified RT-PCR assay to measure MDR1 mRNA levels in osteosarcoma specimens collected from various locations and at different treatment stages.

Limitations

The study did not establish a direct correlation between MDR1 expression levels and chemotherapy response.

Participant Demographics

All patients presented free of metastatic disease and received neoadjuvant chemotherapy including doxorubicin.

Statistical Information

P-Value

0.07

Statistical Significance

p=0.07

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication